Combined urine test for T2:ERG, PCA3 ups prostate CA detection

May 22, 2017

(HealthDay)—Testing for combined urinary PCA3 and TMPRSS2:ERG (T2:ERG) RNA can improve detection of prostate cancer, according to a study published online May 18 in JAMA Oncology.

Martin G. Sanda, M.D., from the Emory University School of Medicine in Atlanta, and colleagues conducted a multicenter diagnostic evaluation and validation in academic and community-based ambulatory urology clinics. A sample of men presenting for first-time without preexisting prostate cancer were enrolled: 516 in the developmental cohort and 561 in the validation cohort. Urinary PCA3 and T2:ERG RNA were measured before prostate biopsy.

The researchers found that at thresholds that preserved 95 percent sensitivity for detecting aggressive prostate cancer, combining testing of urinary T2:ERG and PCA3 improved specificity from 18 to 39 percent in the developmental cohort. Improvement of specificity was also seen in the validation cohort (from 17 to 33 percent), while for aggressive prostate detection, high sensitivity (93 percent) was preserved. Using the urine assay results to select men for biopsy would have resulted in 42 percent of unnecessary prostate biopsies being averted. In cost analysis, the urinary testing algorithm was found to have greater potential benefit for restricting biopsy in younger men.

"Combined urinary testing for T2:ERG and PCA3 can avert unnecessary while retaining robust sensitivity for detecting aggressive with consequent potential health care cost savings," the authors write.

Several authors disclosed financial ties to pharmaceutical and diagnostic companies, including Hologic, which manufactures the Progensa PCA3 assay and is a licensee of the diagnostic field of use for T2:ERG.

Explore further: PCA3 assay ups predictive accuracy for repeat biopsy

More information: Abstract/Full Text

Related Stories

PCA3 assay ups predictive accuracy for repeat biopsy

June 13, 2013
(HealthDay)—For men with at least one prior negative biopsy, urinary PCA3 scores, together with serum prostate-specific antigen and other clinical information, improve the prediction accuracy for repeat biopsy outcome, ...

Surveillance biopsy timing not tied to reclassification

April 22, 2017
(HealthDay)—Timing of the first active surveillance biopsy is not associated with increased adverse reclassification of prostate cancer, according to a study published in the April issue of The Journal of Urology.

Urine-based test improves on PSA for detecting prostate cancer

May 18, 2015
A new urine-based test improved prostate cancer detection - including detecting more aggressive forms of prostate cancer - compared to traditional models based on prostate serum antigen, or PSA, levels, a new study finds.

Increase in prostate needle biopsy-linked infection in N.Y.

April 18, 2017
(HealthDay)—Infectious complications after prostate needle biopsy increased from 2011 to 2014 across New York State, according to a study published in the April issue of The Journal of Urology.

One in four men with suspected prostate cancer could avoid unnecessary biopsy if given an MRI scan first

January 20, 2017
Giving men with suspected prostate cancer an MRI scan could improve diagnosis and save those who do not have aggressive cancers from having an unnecessary biopsy, according to a study published in The Lancet.

Recommended for you

Marker found for condition that causes numerous tumors

October 23, 2018
UT Southwestern researchers have made a major advance in uncovering the biology of how thousands of disfiguring skin tumors occur in patients troubled by a genetic disorder called neurofibromatosis type 1 (NF1). This scientific ...

New kind of compound shows early promise against prostate cancer

October 23, 2018
A new type of molecule blocks the action of genes that drive the growth of therapy-resistant prostate cancer, a new study finds.

Urban and rural rates of childhood cancer survival the same, study finds

October 23, 2018
Childhood and adolescent cancer survival in the United States does not vary by rural/urban residence at the time of diagnosis, finds a new study from the Brown School at Washington University in St. Louis.

Pancreatic cancer genetic marker may predict outcomes with radiation therapy

October 22, 2018
Pancreatic cancer is one of the most difficult cancers to treat and is a leading cause of cancer-related deaths. Now, Sidney Kimmel Cancer Center—Jefferson Health and Lankenau Institute for Medical Research scientists find ...

RNA thought to spread cancer shows ability to suppress breast cancer metastasis

October 22, 2018
Researchers at The University of Texas MD Anderson Cancer Center have discovered that a form of RNA called metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) appears to suppress breast cancer metastasis in mice, ...

Targeting a hunger hormone to treat obesity

October 22, 2018
About 64 per cent of Canadian adults are overweight or obese, according to Health Canada. That's a problem, because obesity promotes the emergence of chronic diseases such as type 2 diabetes, heart disease and some cancers.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.